Lapatinib (Tykerb), a small molecule tyrosine kinase inhibitor which targets both epidermal growth factor receptor (EGFR) and HER2, is effective in the treatment of some trastuzumab-resistant HER2-positive breast cancers in vitro and in vivo [6–8]. The gene discussed is EGFR; the disease is breast carcinoma.